A Look Inside the Chart, Technical Insights - Research on LivePerson, Pharmacyte Biotech, Agenus, and Straight Path Communications

NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: LivePerson Inc (NASDAQ: LPSN), Pharmacyte Biotech Inc (OTC: PMCB), Agenus Inc (NASDAQ: AGEN) and Straight Path Communications Inc (NYSE: STRP). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

To access our full PDF Research Packages for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

LPSN Research Package: http://www.traders-choice.com/pdf?s=LPSN

PMCB Research Package: http://www.traders-choice.com/pdf?s=PMCB

AGEN Research Package: http://www.traders-choice.com/pdf?s=AGEN

STRP Research Package: http://www.traders-choice.com/pdf?s=STRP

============

Highlights from today's reports include:

On Monday, November 23, 2015, the NASDAQ Composite ended at 5,102.48, down 0.05%, the Dow Jones Industrial Average edged 0.17% lower, to finish the day at 17,792.68, and the S&P 500 closed at 2,086.59, down 0.12%.

- LivePerson Inc's stock advanced 0.13% to close Monday's session at USD 7.51. The share price vacillated between USD 7.39 and USD 7.57. The stock recorded a trading volume of 0.19 million shares, which was below its 50-day daily average volume of 0.42 million shares and below its 52-week average volume of 0.35 million shares. Over the last three days LivePerson Inc's shares have advanced 1.21% and in the past one week it has moved up 0.67%. However, in the last six months, the stock has lost 16.00%. The stock is at a price to book (MRQ) ratio of 2.34. The historical PB ratio is near to 4.43. Additionally, the stock is trading at a price to cash flow (TTM) ratio of 19.39 and price to sales (TTM) ratio of 1.81. Further, the stock is trading below its 50-day and 200-day moving averages of USD 7.79 and USD 8.86, respectively.

- Pharmacyte Biotech Inc's stock edged lower by 1.96% to close Monday's session at USD 0.0852. The company's shares oscillated between USD 0.0850 and USD 0.0880. The stock recorded a trading volume of 1.46 million shares, which was below its 50-day daily average volume of 1.88 million shares and below its 52-week average volume of 2.38 million shares. Over the last three days, Pharmacyte Biotech Inc's shares have declined by 5.86% and in the past one week it has moved down 11.06%. Moreover, the stock is trading below its 50-day and 200-day moving averages of USD 0.10 and USD 0.11, respectively with a Relative Strength Index (RSI) of 50.77. Additionally, the company has a Market Value of USD 63.34 million and Enterprise Value of USD 64.00 million with a price to book (MRQ) ratio of 9.66.

- The stock of Agenus Inc lost 1.77% to close Monday's session at USD 4.43. The shares of the company moved in the range of USD 4.35 and USD 4.49. A trading volume of 1.51 million shares was recorded, which was lower than its 150-day daily average volume of 1.56 million shares and below its 52-week average volume of 1.59 million shares. Over the last five days, Agenus Inc's shares have advanced 0.68%. However, over the last three months, the stock has declined 32.57% and in the past six months, the shares have registered a loss of 36.80%. The stock is at a price to book (MRQ) ratio of 8.52. The historical PB ratio is near to 10.82. Further, the stock is trading at a price to sales (TTM) ratio of 20.23. The company has a Market Value of USD 374.98 million and Enterprise Value of USD 293.32 million with an EV/Revenue (TTM) ratio of 15.60.

- Straight Path Communications Inc's stock decreased by 9.28% to close Monday's session at USD 7.82. The company's shares fluctuated in the range of USD 7.62 and USD 8.80, marking a new 52-week low during the session. A total of 0.73 million shares exchanged hands, which surpassed its 50-day daily average volume of 0.68 million shares and was above its 52-week average volume of 0.23 million shares. The company has a Market Value of USD 94.72 million and Enterprise Value of USD 76.10 million with an EV/Revenue (TTM) ratio of 5.75. Additionally, the stock is trading at a price to sales (TTM) ratio of 7.89 and price to book (MRQ) ratio of 5.61. Over the last three days Straight Path Communications Inc's shares have declined by 12.53% and in the past one week it has moved down 23.11%. Furthermore, over the last three months, the stock has lost 63.30%.

--

About Trader's Choice:

Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press (at) traders-choice.com

SOURCE: Trader's Choice


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.